NCT00492063View on ClinicalTrials.gov

Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly

PHASE3CompletedINTERVENTIONAL
Enrollment

2,654

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

December 31, 2004

Study Completion Date

May 31, 2005

Conditions
Influenza
Interventions
BIOLOGICAL

Cell culture-derived trivalent subunit influenza vaccine (cTIV)

One vaccination (0.5 mL) of cell culture-derived influenza vaccine (cTIV) was administered in the deltoid muscle

BIOLOGICAL

Egg-derived trivalent subunit influenza vaccine (TIV)

One vaccination (0.5 mL) of egg-derived influenza virus vaccine (TIV) was administered in the deltoid muscle

Trial Locations (5)

25-381

Wojewódzki Szpital Dzieciecy, Ul. Langiewicza 2

31-832

N ZOZ Jagiellonskie, Centrum Medyczne Sp. z o.o., Os. Jagiellonskie 1

31-115

"Praktyka Grupowa Lekarzy POZ Familia", Pl. Sikorskiego 6a

31-202

Szpital Jana Pawła II, Ul. Pradnicka 80

30-969

Centrum Farmakologii Klinicznej, Krakow

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY